<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014997</article-id><article-id pub-id-type="pmcid-ver">PMC2014997.1</article-id><article-id pub-id-type="pmcaid">2014997</article-id><article-id pub-id-type="pmcaiid">2014997</article-id><article-id pub-id-type="pmid">11012554</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00269.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Population Pharmacokinetics</subject></subj-group></article-categories><title-group><article-title>Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Freyer</surname><given-names initials="G">Gilles</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tranchand</surname><given-names initials="B">Brigitte</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ligneau</surname><given-names initials="B">Blandine</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ardiet</surname><given-names initials="C">Claude</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Souquet</surname><given-names initials="PJ">Pierre-Jean</given-names></name><xref ref-type="aff" rid="au3">3</xref><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Court-Fortune</surname><given-names initials="I">Isabelle</given-names></name><xref ref-type="aff" rid="au4">4</xref><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Riou</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="au4">4</xref><xref ref-type="aff" rid="au6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rebattu</surname><given-names initials="P">Paul</given-names></name><xref ref-type="aff" rid="au4">4</xref><xref ref-type="aff" rid="au7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boissel</surname><given-names initials="JP">Jean-Pierre</given-names></name><xref ref-type="aff" rid="au8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Trillet-Lenoir</surname><given-names initials="V">V&#233;ronique</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Girard</surname><given-names initials="P">Pascal</given-names></name><xref ref-type="aff" rid="au8">8</xref></contrib><aff id="au1"><label>1</label><institution>Medical Oncology Unit and EA 643, Centre Hospitalier Lyon-Sud</institution><addr-line>Pierre-B&#233;nite, Lyon</addr-line></aff><aff id="au2"><label>2</label><institution>Pharmacology Unit, Centre L&#233;on B&#233;rard</institution><addr-line>Lyon</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Pneumology, Centre Hospitalier Lyon-Sud</institution><addr-line>Pierre-B&#233;nite, Lyon</addr-line></aff><aff id="au4"><label>4</label><institution>Lyon Saint-Etienne Thoracic Oncology Group (GLOT)</institution><addr-line>Lyon and Saint-Etienne</addr-line></aff><aff id="au5"><label>5</label><institution>Department of Pneumology, H&#244;pital Nord</institution><addr-line>Saint-Etienne</addr-line></aff><aff id="au6"><label>6</label><institution>Department of Pneumology, Centre Hospitalier de Valence</institution><addr-line>Valence</addr-line></aff><aff id="au7"><label>7</label><institution>Department of Medical Oncology, Centre L&#233;on B&#233;rard</institution><addr-line>Lyon</addr-line></aff><aff id="au8"><label>8</label><institution>Department of Clinical Pharmacology and EA 643, H&#244;pital Louis Pradel</institution><addr-line>UFR La&#235;nnec, Lyon, France</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence:</italic> Gilles Freyer, MD, Medical Oncology Unit, Centre Hospitalier Lyon-Sud, 69495 Pierre-B&#233;nite c&#233;dex, France. Tel.: 00 33 4 78 86 33 24; Fax: 00 33 4 78 86 33 29; E-mail: <email>Gilles.Freyer@chu-lyon.fr</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2000</year></pub-date><volume>50</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">151582</issue-id><fpage>315</fpage><lpage>324</lpage><history><date date-type="received"><day>21</day><month>12</month><year>1999</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2001</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2013-02-27 00:31:08.053"><day>27</day><month>02</month><year>2013</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0050-0315.pdf"/><abstract><sec><title>Aims</title><p>To determine the population pharmacokinetic (PK) parameters of doxorubicin (Dox), etoposide (Eto) and ifosfamide (Ifo) in small cell lung cancer (SCLC) patients, to assess the potential relationship between those parameters and to estimate the impact of individual morphological and biological covariates on patients' PK parameters.</p></sec><sec sec-type="methods"><title>Methods</title><p>Twenty-four patients with either SCLC limited to the thorax or extensive SCLC entered the study. All but one received at least two 3 day courses of the standard AVI (Dox 50 mg m<sup>&#8722;2</sup> day 1, Eto 120 mg m<sup>&#8722;2</sup> day 1,2,3, Ifo 2000 mg m<sup>&#8722;2</sup> day 1,2) regimen. Individual blood samples were collected during each course and data on 47 courses were available. Data were analysed with the NONMEM program. Dox, Eto and Ifo plasma concentrations were studied with multicompartment (3, 2 and 2, respectively) models. Inter-individual and interoccasion (course-to-course) variabilities were estimated. The influence of individual covariates (age, sex, stage of the disease, weight, height, body-surface area, serum creatinine, total protein, LDH, ASAT, ALAT, alkaline phosphatase, gamma-GT, bilirubin) on PK parameters was also assessed. Correlations between individual doxorubicin PK parameters of Dox, Eto and Ifo were explored by using Pearson's correlation coefficient.</p></sec><sec><title>Results</title><p>Multiple data were available for each patient. Dox clearance (CL) and volume of distribution (<italic>V</italic><sub>d</sub>) were 32.0 l h<sup>&#8722;1</sup> and 9.3 l (Inter-individual variability: 17.2% and 19.2%). Eto CL (l h<sup>&#8722;1</sup>) and <italic>V</italic><sub>d</sub> were, respectively, 3.34&#8211;0.0083* serum creatinine (&#181;mol l<sup>&#8722;1</sup>) and 6.38 l (interindividual variability: 15.6% and 18.7%). Ifo CL and <italic>V</italic><sub>d</sub> at day 1 were 5.6 l h<sup>&#8722;1</sup> and 26.0 l (interindividual variability: 10.1% and 17.2%, respectively). Estimation of course-to-course variability improved the precision of PK models in some cases. No correlation was observed between the respective PK parameters of each drug. Of individual covariates tested, only serum creatinine correlated with Eto CL (<italic>r</italic> = &#8722;0.37, <italic>P</italic> &lt; 0.001). Self-induction of the metabolism of Ifo was apparent (mean CL increase from day 1 to day 2 : 42%) and individually correlated with the CL value at day 1 (<italic>r</italic> = &#8722;0.61, <italic>P</italic> &lt; 0.001).</p></sec><sec><title>Conclusions</title><p>Assessment of potential relationships between individual systemic exposure of chemotherapy and therapeutic endpoints (tumour response, toxicity and survival) will be required to adjust drugs dosages based on individual PK parameters rather than questionable body-surface area. However, all three drugs in the AVI regimen should be monitored simultaneously.</p></sec></abstract><kwd-group><kwd>doxorubicin</kwd><kwd>etoposide</kwd><kwd>ifosfamide</kwd><kwd>population pharmacokinetics</kwd><kwd>small cell lung cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>